NAD+ (nicotinamide adenine dinucleotide) is a naturally occurring dinucleotide coenzyme found in every living cell. It is worth noting upfront that NAD+ is not technically a peptide — unlike the other compounds discussed on this site, it is not built from amino acids. It is included here because it is frequently researched alongside peptides in longevity and cellular metabolism protocols, and researchers working across this field often study it in parallel with compounds like Epithalon and MOTS-c.
NAD+ functions as a central coenzyme in cellular energy metabolism: it acts as an electron carrier in mitochondrial oxidative phosphorylation, a substrate for sirtuin deacetylases (SIRT1–7) involved in gene regulation, and a substrate for PARP enzymes involved in DNA strand break repair.
Why NAD+ Levels Are a Research Focus
Research has documented that NAD+ levels decline with age, attributed to increased consumption by CD38 (an enzyme upregulated with age and inflammation) and PARP (activated by accumulating DNA damage), alongside reduced efficiency of the pathways that resynthesise it. This combination of rising consumption and falling production is the basis for NAD+’s prominence in cellular ageing research.
Biosynthesis Pathways
Two principal pathways are studied in the research literature:
The salvage pathway recycles nicotinamide — a byproduct of NAD+-consuming reactions — back into NAD+, via nicotinamide mononucleotide (NMN) as an intermediate. This pathway accounts for the majority of NAD+ production in most tissues studied.
The Preiss-Handler pathway synthesises NAD+ from dietary niacin via a separate intermediate route.
A relevant nuance for researchers: nicotinamide N-methyltransferase (NNMT), an enzyme elevated in obesity, ageing, and metabolic disease, diverts a portion of recoverable nicotinamide away from the salvage pathway entirely, methylating it for excretion rather than recycling. Some recent research literature has framed NAD+ decline as resulting from the convergence of increased consumption, decreased synthesis, and this active diversion of precursors — rather than any single cause in isolation.
Documented Research Areas
Sirtuin Activation
Because sirtuins (SIRT1–7) are strictly NAD+-dependent enzymes, NAD+ availability is a frequent variable in research examining gene expression related to metabolism, inflammation, and cellular ageing. Research has explored how NAD+-driven sirtuin activation contributes to metabolic regulation and inflammatory signalling in various model systems.
Mitochondrial Function and ATP Production
Given its role in oxidative phosphorylation, research has examined NAD+ availability in relation to ATP production in metabolically active tissues, including skeletal muscle, liver, and neural tissue — positioning it as a tool in mitochondrial efficiency research.
DNA Repair Research
NAD+’s role as a PARP substrate connects it to genomic stability research, since PARP-mediated DNA strand break repair consumes NAD+ as part of its mechanism — a relevant consideration in any study examining the interplay between DNA damage accumulation and cellular NAD+ pools.
NAD+ Versus Its Precursors
A distinction worth making clearly: direct NAD+ delivery bypasses the enzymatic conversion steps required by precursor compounds such as NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside), which must be converted intracellularly before contributing to the NAD+ pool. Research comparing precursor supplementation to direct NAD+ delivery has reported inconsistent dose-response relationships for precursor approaches, with some studies showing diminishing returns at higher precursor doses — a pattern attributed in part to the NNMT diversion pathway described above.
What the Research Does Not Establish
Much of the available human clinical trial data concerns NAD+ precursors (NMN, NR) rather than direct NAD+ administration specifically, and researchers should not assume findings from precursor trials transfer directly to NAD+ itself. Tissue-specific effects are also a documented complexity: research has reported that muscle NAD+ levels respond more consistently to intervention than hepatic NAD+ in some study designs, meaning outcomes may vary considerably depending on the tissue or system under investigation.
As with the peptides discussed elsewhere on this site, the strength of the current evidence is best described as mechanistically well-characterised at the cellular level, with comparatively early-stage data on long-term systemic outcomes.
Sourcing Research-Grade NAD+
Any NAD+ used in a laboratory setting should be accompanied by a batch-specific Certificate of Analysis confirming identity, purity, and screening for relevant contaminants. At Claripep, every batch we stock is independently tested by a third-party laboratory before being made available for purchase.
This article is provided for research and educational purposes only and does not constitute medical advice. All products supplied by Claripep Ltd are intended strictly for laboratory research applications.